1. Product Overview
2. Research Methodology
3. Impact of COVID-19
on Global Adalimumab Market
4. Executive Summary
5. Voice of Customer
5.1. Adalimumab Demand,
By Therapeutic Area
5.2. Adalimumab Demand,
By Region
5.3. Adalimumab Demand,
By Gender
5.4. Adalimumab Demand,
By Patient Population
5.5. Commonly Observed
Side-Effects
5.6. Brand Awareness
6. Pharmacodynamic
Overview of Adalimumab
6.1. Mechanism of Action
6.2. Absorption
6.3. Volume of
Distribution
6.4. Route of Elimination
6.5. Half Life
6.6. Clearance
6.7. Toxicity
7. Clinical Trials
7.1. Ongoing Clinical
Trials
7.2. Completed Clinical
Trials
7.3. Terminated Clinical
Trials
7.4. Clinical Trial
Analysis
8. Patent Analysis
8.1. Patent Granted
8.2. Patent Applications
Filed
9.
Global Adalimumab Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By
Type (Biologics v/s Biosimilars)
9.2.2. By
Product Type (Branded v/s Generics)
9.2.3. By
Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s
Disease, Others)
9.2.4. Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
9.2.5. By
End User (Hospitals & Clinics, Home Healthcare, Others)
9.2.6. By Company (2020)
9.2.7.
By Region
9.3. Product Market Map
10.
North America Adalimumab Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value &
Volume
10.2.
Market Share & Forecast
10.2.1. By
Type
10.2.2. By
Product Type
10.2.3. By
Therapeutic Area
10.2.4. By
Distribution Channel
10.2.5. By
End User
10.2.6. By Country
10.3.
North America: Country Analysis
10.3.1. United States Adalimumab
Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Product Type
10.3.1.2.3.
By Therapeutic Area
10.3.1.2.4.
By Distribution Channel
10.3.1.2.5.
By End User
10.3.2. Mexico Adalimumab
Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Product Type
10.3.2.2.3.
By Therapeutic Area
10.3.2.2.4.
By Distribution Channel
10.3.2.2.5.
By End User
10.3.3. Canada Adalimumab
Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Product Type
10.3.3.2.3.
By Therapeutic Area
10.3.3.2.4.
By Distribution Channel
10.3.3.2.5.
By End User
11.
Europe Adalimumab Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value &
Volume
11.2.
Market Share & Forecast
11.2.1. By
Type
11.2.2. By
Product Type
11.2.3. By
Therapeutic Area
11.2.4. By
Distribution Channel
11.2.5. By
End User
11.2.6. By Country
11.3.
Europe: Country Analysis
11.3.1. France Adalimumab
Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Type
11.3.1.2.2.
By Product Type
11.3.1.2.3.
By Therapeutic Area
11.3.1.2.4.
By Distribution Channel
11.3.1.2.5.
By End User
11.3.2. Germany Adalimumab
Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Type
11.3.2.2.2.
By Product Type
11.3.2.2.3.
By Therapeutic Area
11.3.2.2.4.
By Distribution Channel
11.3.2.2.5.
By End User
11.3.3. United Kingdom Adalimumab
Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Type
11.3.3.2.2.
By Product Type
11.3.3.2.3.
By Therapeutic Area
11.3.3.2.4.
By Distribution Channel
11.3.3.2.5.
By End User
11.3.4. Italy Adalimumab
Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1.
By Type
11.3.4.2.2.
By Product Type
11.3.4.2.3.
By Therapeutic Area
11.3.4.2.4.
By Distribution Channel
11.3.4.2.5.
By End User
11.3.5. Spain Adalimumab
Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1.
By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1.
By Type
11.3.5.2.2.
By Product Type
11.3.5.2.3.
By Therapeutic Area
11.3.5.2.4.
By Distribution Channel
11.3.5.2.5.
By End User
12.
Asia-Pacific Adalimumab Market Outlook
12.1.
Market Size & Forecast
12.1.1. By Value &
Volume
12.2.
Market Share & Forecast
12.2.1. By
Type
12.2.2. By
Product Type
12.2.3. By
Therapeutic Area
12.2.4. By
Distribution Channel
12.2.5. By
End User
12.2.6. By Country
12.3.
Asia-Pacific: Country Analysis
12.3.1. China Adalimumab
Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1.
By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1.
By Type
12.3.1.2.2.
By Product Type
12.3.1.2.3.
By Therapeutic Area
12.3.1.2.4.
By Distribution Channel
12.3.1.2.5.
By End User
12.3.2. India Adalimumab
Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1.
By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1.
By Type
12.3.2.2.2.
By Product Type
12.3.2.2.3.
By Therapeutic Area
12.3.2.2.4.
By Distribution Channel
12.3.2.2.5.
By End User
12.3.3. South Korea Adalimumab
Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1.
By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1.
By Transgenic Crop
12.3.3.2.2.
By Technique
12.3.3.2.3.
By Application
12.3.3.2.4.
By End User
12.3.4. Japan Adalimumab
Market Outlook
12.3.4.1. Market Size & Forecast
12.3.4.1.1.
By Value
12.3.4.2. Market Share & Forecast
12.3.4.2.1.
By Type
12.3.4.2.2.
By Product Type
12.3.4.2.3.
By Therapeutic Area
12.3.4.2.4.
By Distribution Channel
12.3.4.2.5.
By End User
12.3.5. Australia Adalimumab
Market Outlook
12.3.5.1. Market Size & Forecast
12.3.5.1.1.
By Value
12.3.5.2. Market Share & Forecast
12.3.5.2.1.
By Type
12.3.5.2.2.
By Product Type
12.3.5.2.3.
By Therapeutic Area
12.3.5.2.4.
By Distribution Channel
12.3.5.2.5.
By End User
13.
South America Adalimumab Market Outlook
13.1.
Market Size & Forecast
13.1.1. By Value &
Volume
13.2.
Market Share & Forecast
13.2.1. By
Type
13.2.2. By
Product Type
13.2.3. By
Therapeutic Area
13.2.4. By
Distribution Channel
13.2.5. By
End User
13.2.6. By Country
13.3.
South America: Country Analysis
13.3.1. Brazil Adalimumab
Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1.
By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1.
By Type
13.3.1.2.2.
By Product Type
13.3.1.2.3.
By Therapeutic Area
13.3.1.2.4.
By Distribution Channel
13.3.1.2.5.
By End User
13.3.2. Argentina Adalimumab
Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1.
By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1.
By Type
13.3.2.2.2.
By Product Type
13.3.2.2.3.
By Therapeutic Area
13.3.2.2.4.
By Distribution Channel
13.3.2.2.5.
By End User
13.3.3. Colombia Adalimumab
Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1.
By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1.
By Type
13.3.3.2.2.
By Product Type
13.3.3.2.3.
By Therapeutic Area
13.3.3.2.4.
By Distribution Channel
13.3.3.2.5.
By End User
14.
Middle East and Africa Adalimumab Market Outlook
14.1.
Market Size & Forecast
14.1.1. By Value &
Volume
14.2.
Market Share & Forecast
14.2.1. By
Type
14.2.2. By
Product Type
14.2.3. By
Therapeutic Area
14.2.4. By
Distribution Channel
14.2.5. By
End User
14.2.6. By Country
14.3.
MEA: Country Analysis
14.3.1. South Africa Adalimumab
Market Outlook
14.3.1.1. Market Size & Forecast
14.3.1.1.1.
By Value
14.3.1.2. Market Share & Forecast
14.3.1.2.1.
By Type
14.3.1.2.2.
By Product Type
14.3.1.2.3.
By Therapeutic Area
14.3.1.2.4.
By Distribution Channel
14.3.1.2.5.
By End User
14.3.2. Saudi Arabia Adalimumab
Market Outlook
14.3.2.1. Market Size & Forecast
14.3.2.1.1.
By Value
14.3.2.2. Market Share & Forecast
14.3.2.2.1.
By Type
14.3.2.2.2.
By Product Type
14.3.2.2.3.
By Therapeutic Area
14.3.2.2.4.
By Distribution Channel
14.3.2.2.5.
By End User
14.3.3. UAE Adalimumab
Market Outlook
14.3.3.1. Market Size & Forecast
14.3.3.1.1.
By Value
14.3.3.2. Market Share & Forecast
14.3.3.2.1.
By Type
14.3.3.2.2.
By Product Type
14.3.3.2.3.
By Therapeutic Area
14.3.3.2.4.
By Distribution Channel
14.3.3.2.5.
By End User
15. Market Dynamics
15.1.
Drivers
15.2.
Challenges
16. Market Trends &
Developments
17. Competitive
Landscape
17.1.
Abbvie Inc.
17.2.
Pfizer, Inc.
17.3.
Amgen Inc.
17.4.
Novartis AG
17.5.
Torrent
Pharmaceuticals Ltd.
17.6.
Cadila Healthcare
Limited
17.7.
Boehringer Ingelheim
International GmbH
17.8.
Mylan N.V.
17.9.
Hetero Biopharma Ltd
17.10.
Samsung Bioepis Co
Ltd.
18.
Strategic
Recommendations
19.
About Us &
Disclaimer
In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com